Evidence Snapshot

JAK2/TYK2

CHEMBL3301392 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:24:30Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:24 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3301392

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats JAK2/TYK2 as ChEMBL target CHEMBL3301392, mapped to UniProt O60674. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

JAK2/TYK2

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL3301392

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

O60674

Tyrosine-protein kinase JAK2

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why JAK2/TYK2 matters

As of 2026-09-13

JAK2/TYK2 is reviewed as Tyrosine-protein kinase JAK2 (UniProt O60674); the current evidence base includes 5 approved drugs, 56 compounds, and 27 assays, with lead potency reaching pChEMBL 10.3.

Protein context

Tyrosine-protein kinase JAK2

Tyrosine-protein kinase JAK2 Sequence length is 1132 aa.

Review this target as JAK2/TYK2, mapped to UniProt O60674. ChEMBL maps the protein component as Tyrosine-protein kinase JAK2. Sequence length is 1132 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O60674 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 56 compounds, and 27 assays for this target. The dominant activity type is IC50. CHEMBL5418288 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL5418288 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine

5 approved pChEMBL 10.3

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why JAK2/TYK2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O60674, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 68.0, EC50: 1.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5418288	10.3	IC50	—
No preferred name CHEMBL5420928	10.1	IC50	—
No preferred name CHEMBL5413489	9.5	IC50	—
No preferred name CHEMBL5440264	9.4	IC50	—
No preferred name CHEMBL5420349	9.0	IC50	—